Revenues remained flat at | 4376 crore YoY due to 25.1% YoY decline in US revenues to | 856 crore, attributable mainly to high base of gSensipar. On the other hand, domestic formulations grew 15.3% to | 1730 crore. EBITDA margins fell 735 bps YoY to 14.5% mainly due to a sharp drop in gross margins (61.4% vs. 66.3% in Q4FY19). EBITDA de-grew 34.1% YoY to | 633.5 crore. Net profit fell 33.0% YoY to | 246.0 crore due to a below...